Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05266417 · ClinicalTrials.gov registry record · Phase 2

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

A Phase 2 study of Parkinson Disease, sponsored by Gateway Institute for Brain Research.

Recruiting
Registry status
Phase 2
Development phase
56
Enrollment target
2
Study locations

NCT05266417 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Gateway Institute for Brain Research. The registered enrollment target is 56 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05266417, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Gateway Institute for Brain Research.

RECRUITING
Registry status
Phase 2
Development phase
56 participants
Enrollment target
2
Study locations

Study Summary

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG INS-GSH
  • DRUG Matched Placebos

Study Locations (2)

Florida

  • Institute for Neuroimmune Medicine - Davie
  • Las Mercedes Medical Research - Hialeah

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2022-02-07
Est. Completion 2027-01-30
Phase Phase 2

Sponsor

Gateway Institute for Brain Research

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05266417

The ClinicalTrials.gov registry entry for NCT05266417 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Gateway Institute for Brain Research, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which INS-GSH is the first listed.

NCT05266417 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05266417 about?

NCT05266417 is a clinical study titled "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease". This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

What is the current status of trial NCT05266417?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-02-07. Estimated completion is 2027-01-30.

What conditions does trial NCT05266417 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT05266417?

The interventions under investigation include: INS-GSH (DRUG), Matched Placebos (DRUG).

Who is sponsoring clinical trial NCT05266417?

This trial is sponsored by Gateway Institute for Brain Research, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05266417 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.